Current and emerging medical treatments for non-small cell lung cancer: A primer for pulmonologists

Respiratory Medicine

Volumn 106, Issue 4, 2012, Pages 473-492

  Mazzone, Peter ^a   Mekhail, Tarek ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Epidermal growth factor receptor inhibition; Non small cell lung cancer; Vascular endothelial growth factor inhibition

Indexed keywords

AFATINIB; AFLIBERCEPT; ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; MOTESANIB; NAVELBINE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VADIMEZAN; VANDETANIB; VASCULOTROPIN INHIBITOR; VINBLASTINE;

ABDOMINAL PAIN; ACNE; ADJUVANT CHEMOTHERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CONSTIPATION; DEHYDRATION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY SKIN; DYSPHONIA; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALAISE; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUROMUSCULAR DISEASE; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; PULMONOLOGY; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; STANDARD; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

EID: 84857918016     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2011.10.016     Document Type: Review

References (164)

1. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology™. Non-Small Cell Lung Cancer V Available at: 2012 http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf accessed 15.09.11 A.D
2. P.A. Wingo, C.J. Cardinez, and S.H. Landis Long-term trends in cancer mortality in the United States, 1930-1998 Cancer 97 2003 3133 3275 (Pubitemid 36667543)
3. O. Gautschi, P.C. Mack, and A.M. Davies Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions Clin Lung Cancer 9 2008 S129 S138
4. T. Boulikas, A. Pantos, and E. Bellis Designing platinum compounds in cancer: structures and mechanisms Cancer Ther 5 2007 537 582
5. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (Pubitemid 34438899)
6. A.T. Fathi, and J.R. Brahmer Chemotherapy for advanced stage non-small cell lung cancer Semin Thorac Cardiovasc Surg 20 2008 210 216
7. A. Ardizzoni, L. Boni, and M. Tiseo Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis J Natl Cancer Inst 99 2007 847 857
8. R.E. Sanborn Cisplatin versus carboplatin in NSCLC: is there one "best" answer? Curr Treat Options Oncol 9 2008 326 342
9. C. Delbaldo, S. Michiels, and N. Syz Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis JAMA 292 2004 470 484 (Pubitemid 38988956)
10. J.O. Park, S.W. Kim, and J.S. Ahn Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer J Clin Oncol 25 2007 5233 5239
11. I.E. Smith, M.E. O'Brien, and D.C. Talbot Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin J Clin Oncol 19 2001 1336 1343 (Pubitemid 32202538)
12. C. von Plessen, B. Bergman, and O. Andresen Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer Br J Cancer 95 2006 966 973 (Pubitemid 44606820)
13. J.J. Lee, and L.N. Harris Chapter 25. Section 8. Antimicrotubule agents V.T. DeVita, T.S. Lawrence, S.A. Rosenberg, Cancer principles & practice of oncology 2008 Lippincott Williams & Wilkins Philadelphia, PA 447 456
14. Z.A. Rasheed, and E.H. Rubin Chapter 25. Section 7. Topoisomerase- interacting agents V.T. DeVita, T.S. Lawrence, S.A. Rosenberg, Cancer principles & practice of oncology 2008 Lippincott Williams & Wilkins Philadelphia, PA 437 447
15. E. Reed Chapter 25. Section 5. Cisplatin and its analogs V.T. DeVita, T.S. Lawrence, S.A. Rosenberg, Cancer principles & practice of oncology 2008 Lippincott Williams & Wilkins Philadelphia, PA 419 426
16. M.W. Saif, and E. Chu Chapter 25. Section 6. Antimetabolites V.T. DeVita, T.S. Lawrence, S.A. Rosenberg, Cancer principles & practice of oncology 2008 Lippincott Williams & Wilkins Philadelphia, PA 427 437
17. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
18. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597 (Pubitemid 41079796)
19. S. Gettinger Targeted therapy in advanced non-small-cell lung cancer Semin Respir Crit Care Med 29 2008 291 301 (Pubitemid 351748435)
20. M. Presta, P. Dell'Era, and S. Mitola Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis Cytokine Growth Factor Rev 16 2005 159 178 (Pubitemid 40616114)
21. A. Levitzki PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases Cytokine Growth Factor Rev 15 2004 229 235 (Pubitemid 38781048)
22. A.F. Gazdar Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 28 2009 S24 S31
23. R.S. Herbst, and A. Sandler Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC Oncologist 13 2008 1166 1176
24. G.A. Silvestri, and M.P. Rivera Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists Chest 128 2005 3975 3984 (Pubitemid 43062660)
25. ® (bevacizumab) solution for intravenous infusion [package insert] 2011 Genentech, Inc. South San Francisco, CA
26. ® (erlotinib tablets) [package insert]. South San Franscisco, CA: Genentech, Inc.
27. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
28. K. Suda, R. Onozato, and Y. Yatabe EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 4 2009 1 4
29. ® (gefitinib tablets) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
30. K. Imai, and A. Takaoka Comparing antibody and small-molecule therapies for cancer Nat Rev Cancer 6 2006 714 727 (Pubitemid 44286003)
31. D.R. Camidge, Y. Bang, and E.L. Kwak Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) J Clin Oncol 2011 29
32. L. Crino, D. Kim, and G.J. Riely Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 J Clin Oncol 2011 29 Abstract 7514
33. N.P. van Erp, R.H. Mathijssen, and V. van d Myelosuppression by sunitinib is flt-3 genotype dependent Br J Cancer 103 2010 757 758
34. R.S. Herbst Toxicities of antiangiogenic therapy in non-small-cell lung cancer Clin Lung Cancer 8 2006 S23 S30
35. R. Perez-Soler Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncol (Williston Park) 17 2003 23 28
36. S. Ricciardi, S. Tomao, and M.F. de Toxicity of targeted therapy in non-small-cell lung cancer management Clin Lung Cancer 10 2009 28 35
37. S. Tsimboukis, I. Merikas, and E.M. Karapanagiotou Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management Clin Lung Cancer 10 2009 106 111
38. M. Tiseo, M. Bartolotti, and F. Gelsomino Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC) Drug Des Devel Ther 4 2010 81 98
39. R. Iyer, and A. Bharthuar A review of erlotinib-an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor Expert Opin Pharmacother 11 2010 311 320
40. R. Rosell, J. Gomez-Codina, and C. Camps A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer N Engl J Med 330 1994 153 158 (Pubitemid 24026882)
41. J.A. Roth, F. Fossella, and R. Komaki A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer J Natl Cancer Inst 86 1994 673 680
42. K.M. Pisters, E. Vallieres, and J.J. Crowley Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial J Clin Oncol 28 2010 1843 1849
43. E. Lim, G. Harris, and A. Patel Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials J Thorac Oncol 4 2009 1380 1388
44. R. Arriagada, B. Bergman, and A. Dunant Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360 (Pubitemid 38101630)
45. J.Y. Douillard, R. Rosell, and L.M. De Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 2006 719 727 (Pubitemid 44283661)
46. T. Winton, R. Livingston, and D. Johnson Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597 (Pubitemid 41007845)
47. J.P. Pignon, H. Tribodet, and G.V. Scagliotti Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
48. C.A. Butts, K. Ding, and L. Seymour Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10 J Clin Oncol 28 2010 29 34
49. R. Arriagada, A. Dunant, and J.P. Pignon Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer J Clin Oncol 28 2010 35 42
50. L.A. Robinson, J.C. Ruckdeschel, and H. Wagner Jr. Treatment of non-small cell lung cancer-stage IIIA: aCCP evidence-based clinical practice guidelines (2nd edition) Chest 132 2007 243S 265S (Pubitemid 47502811)
51. W.J. Scott, J. Howington, and S. Feigenberg Treatment of non-small cell lung cancer stage I and stage II: aCCP evidence-based clinical practice guidelines (2nd edition) Chest 132 2007 234S 242S (Pubitemid 47502810)
52. G.V. Scagliotti, R. Fossati, and V. Torri Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer J Natl Cancer Inst 95 2003 1453 1461 (Pubitemid 37279330)
53. G.M. Strauss, J.E. Herndon, and M.A. Maddaus Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups J Clin Oncol 26 2008 5043 5051
54. Y. Ohe, Y. Ohashi, and K. Kubota Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan Ann Oncol 18 2007 317 323 (Pubitemid 46323100)
55. F. Fossella, J.R. Pereira, and J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024 (Pubitemid 46606280)
56. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991 (Pubitemid 44343542)
57. A. Potti, S. Mukherjee, and R. Petersen A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer N Engl J Med 355 2006 570 580 (Pubitemid 44200650)
58. A.C. Borczuk, R.L. Toonkel, and C.A. Powell Genomics of lung cancer Proc Am Thorac Soc 6 2009 152 158
59. B.E. Lally, D. Zelterman, and J.M. Colasanto Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database J Clin Oncol 24 2006 2998 3006 (Pubitemid 46638932)
60. K.S. Albain, R.S. Swann, and V.W. Rusch Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial Lancet 374 2009 379 386
61. J.P. van Meerbeeck, G.W. Kramer, and P.E. Van Schil Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer J Natl Cancer Inst 99 2007 442 450 (Pubitemid 47073567)
62. R.O. Dillman, J. Herndon, and S.L. Seagren Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 1996 1210 1215 (Pubitemid 26302034)
63. W. Sause, P. Kolesar, and S.I.V. Taylor Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest 117 2000 358 364 (Pubitemid 30111583)
64. K. Furuse, M. Fukuoka, and M. Kawahara Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699 (Pubitemid 29415225)
65. W.J. Curran Jr., R. Paulus, and C.J. Langer Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 J Natl Cancer Inst 2011
66. J.R. Jett, S.E. Schild, and R.L. Keith Treatment of non-small cell lung cancer, stage IIIB: aCCP evidence-based clinical practice guidelines (2nd edition) Chest 132 2007 266S 276S (Pubitemid 47502812)
67. M.R. Green, H. West, and M.A. Socinski Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer J Thorac Oncol 4 2009 983 987
68. N. Hanna, M. Neubauer, and C. Yiannoutsos Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology J Clin Oncol 26 2008 5755 5760
69. C.G. Azzoli, S. Baker Jr., and S. Temin American Society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6266
70. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials J Clin Oncol 26 2008 4617 4625
71. M.A. Socinski, R. Crowell, and T.E. Hensing Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 2007 277S 289S (Pubitemid 47502813)
72. P.J. Souquet, F. Chauvin, and J.P. Boissel Polychemotherapy in advanced non small cell lung cancer: a meta-analysis Lancet 342 1993 19 21 (Pubitemid 23183916)
73. R. Booton, P. Lorigan, and H. Anderson A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1) Ann Oncol 17 2006 1111 1119 (Pubitemid 43985247)
74. S. Danson, M.R. Middleton, and K.J. O'Byrne Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma Cancer 98 2003 542 553 (Pubitemid 36885995)
75. K. Kelly, J. Crowley, and P.A. Bunn Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218 (Pubitemid 32591438)
76. E.F. Smit, J.P. van Meerbeeck, and P. Lianes Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975 J Clin Oncol 21 2003 3909 3917 (Pubitemid 46606203)
77. P. Zatloukal, L. Petruzelka, and M. Zemanova Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study Lung Cancer 46 2004 87 98 (Pubitemid 39201387)
78. F.J. Barata, B. Parente, and E. Teixeira Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine J Thorac Oncol 2 2007 S666 Abstract P2-235
79. M.A. Socinski, M.J. Schell, and A. Peterman Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 2002 1335 1343 (Pubitemid 34182817)
80. Y.Y. Soon, M.R. Stockler, and L.M. Askie Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials J Clin Oncol 27 2009 3277 3283
81. M.A. Socinski, I.N. Bondarenko, and N.A. Karaseva Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 2010 28 Abstract LBA7511
82. M. Reck, J. von Pawel, and P. Zatloukal Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol 21 2010 1804 1809
83. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
84. M.A. Socinski, C.J. Langer, and J.E. Huang Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases J Clin Oncol 27 2009 5255 5261
85. V.A. Miller, P. O'Conner, and C. Soh A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 27 2009 LBA8002
86. A.J. Wozniak, J. Garst, and M. Jahanzeb Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS) J Clin Oncol 2010 28 Abstract 7618
87. M. Reck, J. von Pawel, and P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 2009 1227 1234
88. S.V. Sharma, D.W. Bell, and J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
89. P.A. Janne, X.F. Wang, and M.A. Socinski Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 J Clin Oncol 2010 28 Abstract 7503
90. A. Inoue, K. Kobayashi, and K. Usui First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 2009 1394 1400
91. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
92. R. Rosell, T. Moran, and C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
93. M. Fukuoka, Y.L. Wu, and S. Thongprasert Biomarker analyses and Final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus Carboplatin/Paclitaxel in Clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
94. R.S. Herbst, G. Giaccone, and J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 2004 785 794 (Pubitemid 41103589)
95. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784 (Pubitemid 41103588)
96. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552 (Pubitemid 46733081)
97. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
98. R. Pirker, J.R. Pereira, and A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
99. T.J. Lynch, T. Patel, and L. Dreisbach Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 2010 911 917
100. N. Thatcher, A. Chang, and P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
101. F.A. Shepherd, P.J. Rodrigues, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
102. E.S. Kim, V. Hirsh, and T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
103. N. Godin-Heymann, L. Ulkus, and B.W. Brannigan The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor Mol Cancer Ther 7 2008 874 879 (Pubitemid 351551040)
104. N.A. Cipriani, O.O. Abidoye, and E. Vokes MET as a target for treatment of chest tumors Lung Cancer 63 2009 169 179
105. D.R. Camidge, R. Dziadziuszko, and F.R. Hirsch The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers Clin Lung Cancer 10 2009 262 272
106. T. Sasaki, S.J. Rodig, and L.R. Chirieac The biology and treatment of EML4-ALK non-small cell lung cancer Eur J Cancer 46 2010 1773 1780
107. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
108. D.W. Wong, E.L. Leung, and K.K. So The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 115 2009 1723 1733
109. T. Ciuleanu, T. Brodowicz, and C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
110. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
111. P.M. Fidias, S.R. Dakhil, and A.P. Lyss Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 2009 591 598
112. T.J. Lynch, R. Raju, and M. Lind Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report Proc Am Soc Clin Oncol 22 2003 623 Abstract 2504
113. L. Paz-Ares, J.Y. Douillard, and P. Koralewski Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer J Clin Oncol 24 2006 1428 1434 (Pubitemid 46622009)
114. D. Bissett, K.J. O'Byrne, and P.J. von Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer J Clin Oncol 23 2005 842 849 (Pubitemid 46224184)
115. N.B. Leighl, L. Paz-Ares, and J.Y. Douillard Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18 J Clin Oncol 23 2005 2831 2839 (Pubitemid 46179474)
116. Schering-Plough Schering-Plough discontinues phase III clinical study of Sarasar(TM) (Lonafarnib) in non-small-cell lung cancer. Press release Available at: February 5, 2010 http://prnewswire.us/cgi-bin/stories.pl?ACCT=104&STORY= /www/story/02-05-2004/0002104279&EDATE= accessed 27.07.10
117. G. Scagliotti, and R. Govindan Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer Oncologist 15 2010 436 446
118. Bayer Healthcare Pharmaceuticals Inc, Onyx Pharmaceuticals Inc Phase 3 trial of Nexavar in first-line advanced non-small cell lung cancer does not meet primary endpoint of overall survival. Press release June 14, 2010 Available at: http://www.onyx-pharm.com/view.cfm/685/Phase-3-Trial-of-Nexavar-in-First-Line- Advanced-Non-Small-Cell-Lung-Cancer-Does-Not-Meet-Primary-Endpoint-of-Overall- Survival accessed 27.07.10
119. Antisoma plc ATTRACT-1 phase III trial of ASA404 halted following interim analysis. Press release March 29, 2010 Available at: http://www.antisoma.com/ asm/media/press/pr2010/2010-03-29/ accessed 27.07.10
120. F. Hilberg, G.J. Roth, and M. Krssak BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 68 2008 4774 4782
121. G.J. Roth, A. Heckel, and F. Colbatzky Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) J Med Chem 52 2009 4466 4480
122. P. Nikolinakos, and J.V. Heymach The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies J Thorac Oncol 3 2008 S131 S134 (Pubitemid 351786743)
123. NCIC Clinical Trials Group. Site Committee Open/Closed/Planned/On Hold/Withdrawn studies. Available at: http://www.ctg.queensu.ca/public/Clinical- Trials/ph3-trial-accrual-closed.htm accessed 11.08.11.
124. A. Polverino, A. Coxon, and C. Starnes AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Res 66 2006 8715 8721 (Pubitemid 44449188)
125. G. Scagliotti, I. Vynnychenko, and Y. Ichinose An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) J Clin Oncol 2011 29 Abstract LBA7512
126. R. Kumar, V.B. Knick, and S.K. Rudolph Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol Cancer Ther 6 2007 2012 2021 (Pubitemid 47052491)
127. K. Podar, G. Tonon, and M. Sattler The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma Proc Natl Acad Sci U S A 103 2006 19478 19483 (Pubitemid 46026056)
128. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
129. G. Scagliotti, S. Novello, and J. von Pawel Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1835 1842
130. ® (sunitinib malate) capsules, oral [package insert] 2011 Pfizer Inc New York, NY
131. A.C. Lockhart, M.L. Rothenberg, and J. Dupont Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 2010 207 214
132. S. Novello, R. Ramlau, and V.A. Gorbunova Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): Final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL) Abstract associated with oral presentation at: the 14th Biennial World Conference on Lung Cancer; July
133. C. Gridelli, A. Rossi, and P. Maione Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer Oncologist 14 2009 612 620
134. P.N. Lara Jr., J.Y. Douillard, and K. Nakagawa Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer J Clin Oncol 29 2011 2965 2971
135. Pfizer Inc. Pfizer discontinues a phase 3 trial of figitumumab in non-small cell lung cancer (NSCLC) for futility. Available at: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId= news-view&newsId=20091229005376&newsLang=en. accessed 15.04.10.
136. Pfizer Inc. Pfizer discontinues a phase 3 trial of figitumumab and erlotinib in non-small cell lung cancer (NSCLC) for futility. Available at: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId= news-view&newsId=20091229005376&newsLang=en. accessed 15.04.10.
137. J. Crawford, P. Swanson, and D. Prager Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis Eur J Cancer Suppl 3 2005 324 Abstract 1123
138. A.W. Tolcher, J. Sarantopoulos, and A. Patnaik Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 J Clin Oncol 27 2009 5800 5807
139. J. Sarantopoulos, A.C. Mita, and M. Mulay A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G) J Clin Oncol 26 2008 3583
140. I. Puzanov, J. Sarantopoulos, and J. Gilbert Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors J Clin Oncol 28 2010 3018
141. C.S. Higano, E.Y. Yu, and S.H. Whiting A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors J Clin Oncol 25 2007 3505
142. F. Atzori, J. Tabernero, and A. Cervantes A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors J Clin Oncol 26 2008 3519
143. M. Hidalgo, M. Tirado Gomez, and N. Lewis A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule J Clin Oncol 26 2008 3520
144. D. Li, L. Ambrogio, and T. Shimamura BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
145. N. Yamamoto, N. Katakami, and S. Atagi A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib or gefitinib Poster presented at: the Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2011; Chicago, IL 2011 Abstract 7524
146. V.A. Miller, V. Hirsh, and J. Cadranel Subgroup analysis of LUX-Lung 1: a randomized phase III trial of afatinib (BIBW 2992) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib J Thorac Oncol 2010 5 Abstract LBPL3
147. J.A. Engelman, K. Zejnullahu, and C.M. Gale PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib Cancer Res 67 2007 11924 11932
148. M. Reck, R. Kaiser, and C. Eschbach A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer Ann Oncol 22 2011 1374 1381
149. G.D. Goss, A. Arnold, and F.A. Shepherd Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study J Clin Oncol 28 2010 49 55
150. G.K. Dy, S.J. Mandrekar, and G.D. Nelson A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 28 2010 7603
151. G.R. Blumenschein Jr., F. Kabbinavar, and H. Menon A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer Ann Oncol 2011 doi: 10.1093
152. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
153. N. Altorki, M.E. Lane, and T. Bauer Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer J Clin Oncol 28 2010 3131 3137
154. S. Novello, G.V. Scagliotti, and R. Rosell Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer Br J Cancer 101 2009 1543 1548
155. M.A. Socinski, S. Novello, and J.R. Brahmer Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 2008 650 656 (Pubitemid 351264362)
156. R.H. De Boer, O. Arrieta, and C.H. Yang Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial J Clin Oncol 29 2011 1067 1074
157. R.S. Herbst, Y. Sun, and W.E. Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol 11 2010 619 626
158. R.B. Natale, S. Thongprasert, and F.A. Greco Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 29 2011 1059 1066
159. J. Lee, V. Hirsh, and K. Park Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR) J Clin Oncol 2010 28 Abstract 7525
160. C. Yang, J. Shih, and W. Su A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2) Ann Oncol 21 2010 viii123 Abstract 367PD
161. M.J. Boyer, F.H. Blackhall, and K. Park Efficacy and safety of PF299804 versus erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT) J Clin Oncol 28 2010 LBA7523
162. A. Campbell, K.L. Reckamp, and D.R. Camidge PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): a phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E) J Clin Oncol 28 2010 7596
163. T. Mok, D.R. Spigel, and K. Park Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 7537
164. K. Park, D.S. Heo, and B. Cho PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): a phase (P) I/II study J Clin Oncol 28 2010 7599